Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MTPC to Double Number of Vaccine-Specialized MRs to 50, Eyeing TETRABIK Launch
September 3, 2012
- DSP’s US Subsidiary Sunovion to Acquire Elevation Pharmaceuticals of the US
September 3, 2012
- Shionogi to Embark on Collaborative R&D with 5 Danish Universities
September 3, 2012
- MTPC and Nipro Agree on Dissolution of Joint Venture Bipha
September 3, 2012
- 9 Companies Jointly Apply for Combination Use of 3 Agents for H. Pylori Eradication
September 3, 2012
- Wholesalers and Pharmacies See Contrasting Results in 1st Quarter – Which Side Will Come Out the Winner from Non-yieldable Price Bargaining?
September 3, 2012
- Sosei Committed to Becoming a Japan-Based Global Biopharma: Vice President Akihiro Matsuura
September 3, 2012
- Pfizer Japan Launches RCC Treatment Inlyta
August 31, 2012
- Takeda to Conduct Joint Research with Canadian Institute at Shonan Research Center
August 31, 2012
- Eisai Files NDA for Rufinamide for LGS
August 31, 2012
- Novartis to File for COPD Treatment QVA149 in Japan, EU by End of 2012
August 31, 2012
- Kyowa Kirin Temporarily Suspends Patient Enrollment for PIII Study of Its Anticancer Agent ARQ197 Due to ADR
August 31, 2012
- Ribomic Aims to Commercialize Non-Addictive Analgesic Nucleic Acid Drug
August 30, 2012
- Takeda to Start Local Manufacturing at New Russian Factory around FY2014
August 30, 2012
- IBL, IBR to Codevelop Vaccines Using Transgenic Silkworms
August 30, 2012
- Torii to Exclusively Market JT’s Novel Anti-HIV Drug in Japan
August 30, 2012
- GSK Launches ReQuip CR Tablets; MHLW Recommends Use
August 30, 2012
- Takeda Less Dependent on Japan, US Revenues Due to Expanding Emerging Market Biz: CCO Morich
August 29, 2012
- Takeda Gearing Up for Emerging Market Operations
August 29, 2012
- MTPC, Daiichi Sankyo to Launch DPP-4 Inhibitor Tenelia on Sept. 10
August 29, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…